Valneva (VLS)

Paris
Currency in EUR
3.386
+0.014(+0.42%)
Closed
VLS Scorecard
Full Analysis
Suffers from weak gross profit margins
Unusual trading volume
Fair Value
Day's Range
3.2663.468
52 wk Range
1.7264.298
Key Statistics
Edit
Prev. Close
3.372
Open
3.31
Day's Range
3.266-3.468
52 wk Range
1.726-4.298
Volume
5.6M
Average Vol. (3m)
1.83M
1-Year Change
-1.94%
Book Value / Share
1.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VLS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.750
Upside
+99.35%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year
Show more

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Compare VLS to Peers and Sector

Metrics to compare
VLS
Peers
Sector
Relationship
P/E Ratio
−44.9x−2.2x−0.5x
PEG Ratio
−0.51−0.060.00
Price / Book
3.0x1.1x2.6x
Price / LTM Sales
3.2x4.3x3.0x
Upside (Analyst Target)
99.4%149.1%55.2%
Fair Value Upside
Unlock7.0%9.7%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.750
(+99.35% Upside)

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
-0.2074 / -0.09
Revenue / Forecast
52.94M / 54.35M
EPS Revisions
Last 90 days

People Also Watch

218.27
AAPL
+1.95%
117.70
NVDA
-0.70%
240.00
TCFP
-1.28%
248.71
TSLA
+5.27%
391.26
MSFT
+1.14%

FAQ

What Is the Valneva (VLS) Stock Price Today?

The Valneva stock price today is 3.386

What Stock Exchange Does Valneva Trade On?

Valneva is listed and trades on the Paris stock exchange.

What Is the Stock Symbol for Valneva?

The stock symbol for Valneva is "VLS."

What Is the Valneva Market Cap?

As of today, Valneva market cap is 549.88M.

What is Valneva Earnings Per Share?

The Valneva EPS is -0.084.

What Is the Next Valneva Earnings Date?

Valneva will release its next earnings report on May 07, 2025.

From a Technical Analysis Perspective, Is VLS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.